BioMarin to present new skeletal-dysplasia data at ASBMR

BioMarin said it will present data from 13 studies at the American Society for Bone and Mineral Research annual meeting, including results on VOXZOGO, BMN 333 and BMN 401. The company also noted a recent supplemental NDA submission to the FDA for VOXZOGO in hypochondroplasia.